Trial · NCT00218543
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00218543, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2012-07-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD). Trials, record NCT00218543. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00218543
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- NCT number
- NCT00218543
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
- Interventions
- Atomoxetine
- First posted
- 2005-09-22
- Last updated
- 2019-04-24
- Results first posted
- 2012-07-04
- Limitations and caveats
- Clearly, there are limitations of this study including the high drop-out rate, small sample size, and lack of a control group.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the Adult ADHD Rating Scale (AARS) (30% Reduction) | baseline compared to rating at week 12 or last rating during study participation | AARS is a self report that measures symptoms of adult ADHD. The primary outcome was the percentage of patients achieving a 30% reduction from baseline on the AARS scale. The AARS is scored on a continuous, range 0-54. 0 being no symptoms and 54 being indicative of the most severe level of symptoms. |
| Primary | ADHD Symptoms Based on Adult ADHD Rating Scale Scale (AARS) | measured during 12 weeks or length of study participation | Weekly AARS scores (continuous, range 0-54) were examined with the baseline score compared to that at the last assessment obtained and change in these scores over time. The AARS looks at adult ADHD symptoms. A score of 0 represents no symptoms and 54 would be indicative of the most severe level of symptoms. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | the Adult ADHD Rating Scale (AARS) (30% Reduction) | baseline compared to rating at week 12 or last rating during study participation | All participants | percent of participants | NUMBER |
| PRIMARY | ADHD Symptoms Based on Adult ADHD Rating Scale Scale (AARS) | measured during 12 weeks or length of study participation | Comparing overall baseline scores to end of study scores for patients who had at least two AARS weekly measures completed | scores on a scale | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| the Adult ADHD Rating Scale (AARS) (30% Reduction) | Atomoxetine | 50 | percent of participants | ||
| ADHD Symptoms Based on Adult ADHD Rating Scale Scale (AARS) | Atomoxetine | baseline | 31.4 | Standard Deviation 9.8 | scores on a scale |
| ADHD Symptoms Based on Adult ADHD Rating Scale Scale (AARS) | Atomoxetine | end of study | 21.2 | Standard Deviation 12.4 | scores on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atomoxetine | 20 | |
| Overall Study | COMPLETED | Atomoxetine | 5 | |
| Overall Study | NOT COMPLETED | Atomoxetine | 15 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Gastrointestinal disorders | Atomoxetine | 2 | 20 | 2 |
| other | headache | General disorders | Atomoxetine | 1 | 20 | 1 |
| other | chest pain | Cardiac disorders | Atomoxetine | 1 | 20 | 1 |
| other | anxiety | Psychiatric disorders | Atomoxetine | 2 | 20 | 2 |
| other | dizziness | General disorders | Atomoxetine | 1 | 20 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atomoxetine | ||
| Total, other adverse events | Atomoxetine | 5 | 20 |
| Total, serious adverse events | Atomoxetine | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50DA009236 | Novel Medication Approaches for Substance Abuse | KLEBER, HERBERT DAVID | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC | NATIONAL INSTITUTE ON DRUG ABUSE | 1994 to 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00218543
GET https://conductscience.org/api/trials/v1/NCT00218543/registered